Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
Olivier Devuyst, Arlene B. Chapman, Ron T. Gansevoort, et al.
Journal of the American Society of Nephrology (2016) Vol. 28, Iss. 5, pp. 1592-1602
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Autosomal dominant polycystic kidney disease
Émilie Cornec-Le Gall, Ahsan Alam, Ronald D. Perrone
The Lancet (2019) Vol. 393, Iss. 10174, pp. 919-935
Closed Access | Times Cited: 465
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 6
The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Yuliya Lytvyn, Petter Bjornstad, Daniël H. van Raalte, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 2, pp. 202-231
Open Access | Times Cited: 116
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Roman‐Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, et al.
Nephrology Dialysis Transplantation (2021) Vol. 37, Iss. 5, pp. 825-839
Open Access | Times Cited: 97
Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy
Fouad T. Chebib, Vicente E. Torres
American Journal of Kidney Diseases (2021) Vol. 78, Iss. 2, pp. 282-292
Closed Access | Times Cited: 69
Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
Matthew Gittus, Helen Haley, Tess Harris, et al.
BMC Nephrology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
New treatment paradigms for ADPKD: moving towards precision medicine
Matthew B. Lanktree, Arlene B. Chapman
Nature Reviews Nephrology (2017) Vol. 13, Iss. 12, pp. 750-768
Closed Access | Times Cited: 75
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease
Ron T. Gansevoort, Maatje D.A. van Gastel, Arlene B. Chapman, et al.
Kidney International (2019) Vol. 96, Iss. 1, pp. 159-169
Open Access | Times Cited: 69
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Norberto Perico, Piero Ruggenenti, Annalisa Perna, et al.
PLoS Medicine (2019) Vol. 16, Iss. 4, pp. e1002777-e1002777
Open Access | Times Cited: 58
Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
Bart J. Kramers, Maatje D.A. van Gastel, Wendy E. Boertien, et al.
American Journal of Kidney Diseases (2018) Vol. 73, Iss. 3, pp. 354-362
Open Access | Times Cited: 49
Vasopressin–aquaporin-2 pathway: recent advances in understanding water balance disorders
Marianna Ranieri, Annarita Di Mise, Grazia Tamma, et al.
F1000Research (2019) Vol. 8, pp. 149-149
Open Access | Times Cited: 45
Treatment of Autosomal Dominant Polycystic Kidney Disease
Sara S. Jdiaa, Reem A. Mustafa, Alan S.L. Yu
American Journal of Kidney Diseases (2024)
Open Access | Times Cited: 6
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
Olivier Devuyst, Arlene B. Chapman, Susan E. Shoaf, et al.
Kidney International Reports (2017) Vol. 2, Iss. 6, pp. 1132-1140
Open Access | Times Cited: 41
Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease—A Retrospective Single-Arm Case Series Study
Fumiyuki Morioka, Shinya Nakatani, Hideki Uedono, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6341-6341
Open Access | Times Cited: 12
Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD
Francisco Roca Oporto, Cristina Andrades Gómez, Gema Montilla Cosano, et al.
Kidney International Reports (2024) Vol. 9, Iss. 4, pp. 1031-1039
Open Access | Times Cited: 4
European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care
Tess Harris, Richard Sandford, Brenda de Coninck, et al.
Nephrology Dialysis Transplantation (2017) Vol. 33, Iss. 4, pp. 563-573
Open Access | Times Cited: 38
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Laia Sans-Atxer, Dominique Joly
International Journal of Nephrology and Renovascular Disease (2018) Vol. Volume 11, pp. 41-51
Open Access | Times Cited: 37
<p>Autosomal dominant polycystic kidney disease: updated perspectives</p>
Anjay Rastogi, Khalid Mohammed Ameen, Maha Al-Baghdadi, et al.
Therapeutics and Clinical Risk Management (2019) Vol. Volume 15, pp. 1041-1052
Open Access | Times Cited: 34
Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression
Judith E. Heida, Ron T. Gansevoort, A. Lianne Messchendorp, et al.
Clinical Journal of the American Society of Nephrology (2021) Vol. 16, Iss. 2, pp. 204-212
Open Access | Times Cited: 24
Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial
Eiji Higashihara, Miyuki Matsukawa, Huan Jiang
Clinical and Experimental Nephrology (2025)
Open Access
Spot Versus 24-Hour Urine Osmolality Measurement in Autosomal Dominant Polycystic Kidney Disease: A Diagnostic Test Study
Ayub Akbari, Sriram Sriperumbuduri, Shreepryia Mangalgi, et al.
Kidney Medicine (2025), pp. 100965-100965
Open Access
Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era
Tânia Lapão, Rui Barata, Cristina Jorge, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1121-1121
Open Access
Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease
Steven Soroka, Ahsan Alam, Micheli Bevilacqua, et al.
Canadian Journal of Kidney Health and Disease (2018) Vol. 5
Open Access | Times Cited: 30
Fasting Urinary Osmolality, CKD Progression, and Mortality: A Prospective Observational Study
Nahid Tabibzadeh, Sandra Wagner, Marie Metzger, et al.
American Journal of Kidney Diseases (2019) Vol. 73, Iss. 5, pp. 596-604
Open Access | Times Cited: 29
Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron
Nahid Tabibzadeh, Gilles Crambert
Journal of Internal Medicine (2022) Vol. 293, Iss. 1, pp. 4-22
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top